osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
final survival analysis of #adaura demonstrates remarkable 5-year os benefit across all stage ib - iiia egfr mut nsclc patients, making adjuvant osimertinib the first egfr targeted therapy to demonstrate a survival benefit in this population. #asco23 
DAVA Oncology is a strategic consulting company that offers numerous products and services customized to fit biopharmaceutical drug development needs.